The gut hormone, Glucagon-Like Peptide 2, contributes to the improved glycaemic control observed post-bariatric surgery, as a result of its intestinotrophic effects
BACKGROUND Bariatric surgery, specifically Roux-en-Y Gastric Bypass (RYGB), leads to durable weight loss as well as significant improvements in Type 2 Diabetes (T2D). Despite multiple randomised studies showing superiority of RYGB to maximal medical therapy for treatment of T2D, surgery remains gro...
| Main Author: | |
|---|---|
| Format: | Thesis (University of Nottingham only) |
| Language: | English |
| Published: |
2020
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/59753/ |